George Robert E.
Known title: DirectorCIK: 0001674701
George Robert E.'s purchase track record
George Robert E. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/26/2023 | MBRX | $10K | -51.8% | -63.8% | +14.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MBRX | ▲ Buy | Open Market | 14,493 | $10K | 12/26/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
MBRX Completes Phase 2/3 AML Trial Enrollment, Publishes Cardiac Safety
Moleculin Biotech finished enrolling patients in Part A of its Phase 2/3 MIRACLE study for Annamycin plus cytarabine, keeping the program on schedule for a Q1 2027 data readout. The company also released a peer‑reviewed cardiac safety analysis of Annamycin and presented preclinical data showing the drug can turn cold pancreatic tumors hot through immune‑mediated mechanisms. These updates reinforce the company’s progress in both AML and solid‑tumor indications.
MBRX Completes Phase 2/3 AML Trial Enrollment, Publishes Cardiac Safety. Moleculin Biotech finished enrolling patients in Part A of its Phase 2/3 MIRACLE study for Annamycin plus cytarabine, keeping the program on schedule for a Q1 2027 data readout. The company also released a peer‑reviewed cardiac safety analysis of Annamycin and presented preclinical data showing the drug can turn cold pancreatic tumors hot through immune‑mediated mechanisms. These updates reinforce the company’s progress in both AML and solid‑tumor indications.